# Immorna

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immorna

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.immorna.com
- Total disclosed funding: $115M
- Latest round: Series A (Feb 27, 2023)
- Investors on record: 11

## About

Based in Hangzhou, China, and established in 2019, Immorna is a biotechnology company that focuses on the development of RNA-based therapeutics and vaccines. In March 2020, it established a chemistry, manufacturing, and controls (CMC) lab in Hangzhou, and in August 2020, it established an R&D lab in Shanghai. And in December 2021, it established the good manufacturing practice (GMP)-level factory. And then, in March 2022, it received FDA investigational new drug (IND) Clearance for JCXH-211. Professor, Zihao, Wang, the company's CEO, has over 14 years of biotech R&D and leadership experience and developed self-replicating mRNA CMC platform.

 Immorna engages in the R&D of RNA-based therapeutics and vaccines. It developed CMC platform for RNA synthesis, purification, and analytical testing that is suited for clinical and commercial development. And, it has developed RNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery. Those RNA drugs are treated for cancer immunotherapy, infectious diseases,  rare genetic diseases, and medical cosmetology. Moreover, it provides contract development manufacturing (CDMO ) services, based on its own RNA and LNP platform, and services including sequence design, customized analytical assay development, DNA template manufacturing, mRNA/ LNP production and purification.

## Funding rounds

- Series A, Feb 27, 2023, $100M — Yuexiu Industrial Investment Funds Management, Zheshang Venture Capital, China Growth Capital, Co-Win Ventures, CCT Fund Management, Xiamen C&D Emerging Industry Equity Investment, TigerYeah Capital, GL Ventures, Ruihe Xingye Asset, Tailong VC
- Series A, Feb 1, 2021, $15M — Zheshang Venture Capital, China Growth Capital, Co-Win Ventures
- Angel, Dec 13, 2019 — Co-Win Ventures, Alwin Capital

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Angel, Series A
- Alwin Capital — Angel
- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series A
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series A
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series A
- CCT Fund Management — Series A
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- Ruihe Xingye Asset (https://capitalatlas.ai/funds/ruihe-xingye-asset) — Series A
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series A